


## CI-4AS-1

<b>Cat. No.:</b>	HY-103245
<b>CAS No.:</b>	188589-66-4
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>33</sub> ClN <sub>2</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	441.01
<b>Target:</b>	Androgen Receptor
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	CI-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC <sub>50</sub> = 12 nM), is also an inhibitor of 5α-reductase types I and II (IC <sub>50</sub> = 6 and 10 nM, respectively) <sup>[1][2]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 12 nM (androgen receptor); 6 nM (5α-reductase types I); 10 nM (5α-reductase types II) <sup>[1][2]</sup>								
<b>In Vitro</b>	CI-4AS-1 suppresses MMP-1 promoter activity in 22Rv1 human prostate cancer cells <sup>[1]</sup> . CI-4AS-1 (10 μM) effectively promotes the AR N/C interaction, with an average maximal activity of 35.3% <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	CI-4AS-1 produces no significant reduction in prostate weight in intact animals and in castrates rats caused a significant increase of ventral prostate weight <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>ORX rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.s.; 7 days</td> </tr> <tr> <td>Result:</td> <td>Effect of CI-4AS-1 on prostate and seminal vesicle growth.</td> </tr> </table>	Animal Model:	ORX rats <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	i.s.; 7 days	Result:	Effect of CI-4AS-1 on prostate and seminal vesicle growth.
Animal Model:	ORX rats <sup>[1]</sup>								
Dosage:	10 mg/kg								
Administration:	i.s.; 7 days								
Result:	Effect of CI-4AS-1 on prostate and seminal vesicle growth.								

### REFERENCES

[1]. Schmidt A, et al. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. *J Biol Chem.* 2009 Dec 25;284(52):36367-36376.

[2]. Tolman RL, et al. 4-Methyl-3-oxo-4-aza-5α-androst-1-ene-17β-N-aryl-carboxamides: an approach to combined androgen blockade [5α-reductase inhibition with androgen receptor binding in vitro]. *J Steroid Biochem Mol Biol.* 1997 Mar;60(5-6):303-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA